Skip to main content
. 2020 Aug 4;88:106869. doi: 10.1016/j.intimp.2020.106869

Table 1.

The inclusion and exclusion criteria of the study.

Inclusion criteria Age > 18 years; positive RT-PCR for SARS-CoV-2; IL-6 > 10 pg/mL; severe SARS-CoV-2 infection (defined as: SpO2 < 90, RR > 30, or bilateral progressive lung infiltration); critical SARS-CoV-2 infection (defined as: need for ICU or need for mechanical ventilation); no improvement despite receiving 72 h of standard care; signed informed consent
Exclusion criteria Pregnancy or breastfeeding; mild SARS-CoV-2 infection (defined as: SpO2 > 90 or upper respiratory infection); active infection including tuberculosis or bacterial infections; allergy to tocilizumab or its ingredients; chronic kidney disease (eGFR < 30 mL/min); chronic liver disease (Child-Pugh C and D); patients who did not receive 72 h of standard care; neutropenia (ANC less than 1500/mm3); thrombocytopenia (platelet count less than 150,000/µL), dyslipidemia (total cholesterol and triglycerides more than 200 mg/dL and 150 mg/dL, respectively); receiving any anti-inflammatory agent

RT-PCR, Reverse transcription polymerase chain reaction; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; ANC, absolute neutrophil count.